Published in Annals of the Rheumatic Diseasesthese results reinforce the interest of early treatment with a goal of remission. However, they do not guarantee the same outcome for each patient.
The first two years, an important milestone for preserving your joints
Rheumatoid arthritis is a chronic inflammatory disease that can cause pain, joint swelling and difficulty performing daily activities. Without sufficient control of inflammation, joints can suffer lasting damage.
To limit this risk, doctors favor a so-called “treat-to-target” strategy, which consists of adapting treatments until a defined objective is achieved, generally remission or low disease activity.
The Norwegian ARCTIC study followed newly diagnosed people, managed with strategies aimed at controlling the disease. One also relied on ultrasound to detect persistent inflammation. However, this additional monitoring did not bring any significant benefit compared to the traditional strategy.
Ten years later, more than eight out of ten patients were in remission
The researchers assessed the long-term progress of the participants. Among the 218 people still alive, 179 had usable data after ten years. Result :
82% were in clinical remission.
This remission was defined by a DAS score less than 1.6, which takes into account painful or swollen joints, a blood marker of inflammation and the patient’s assessment.
The X-rays were also encouraging: progression of joint damage was limited, with a median change of two points in the X-ray score used by the researchers.
Another result particularly attracts attention. At ten years old, 89.9% of patients who were in remission after two years of treatment were still in remissioncompared to 73.1% of those who had not achieved this goal at this point.
The authors believe that these results “support current treatment recommendations for rheumatoid arthritis and provide newly diagnosed patients with reassurance that clinical remission, preservation of functional capacity, and favorable long-term survival are realistic goals.”.
An encouraging result, but not a guarantee
These data paint a positive outlook for those recently diagnosed. They suggest that quickly achieving control of the disease is associated with a more favorable long-term outcome.
However, we must remain cautious: the study shows an association, and not a cause and effect relationship. It does not allow us to assert that the remission obtained during the first two years explains, in itself, the results observed ten years later. The treatments received subsequently may also have played a role.
Remission also does not mean that the disease is permanently cured or that a relapse is impossible. At ten years, patients often continued their treatment: 44% took a conventional antirheumatic drug, generally methotrexate, and 35% a biological or targeted treatment. Only 15% had stopped all basic treatments.
Why follow-up remains essential after diagnosis
These results remind us of the importance of early and regular treatment. Treatment can be adjusted based on symptoms, clinical and biological examinations and, if necessary, imaging.
Persistent pain, swollen joints or significant fatigue should be reported to the rheumatologist, even when treatment appears to be effective. It should not be modified or interrupted without medical advice.
The objective is to control inflammation, but also to preserve mobility and autonomy over the years.
Achieving remission early is an encouraging sign, without prejudging each patient’s journey.
What can we learn from it when we are followed in France?
For a recently diagnosed person, these data support a message already familiar to rheumatologists: do not let active inflammation linger. Health Insurance points out that treatment aims to control the disease, limit flare-ups, prevent joint destruction and preserve quality of life. Follow-up examinations for rheumatoid arthritis are used precisely to check whether the objective has been achieved.
This monitoring can be based on clinical examination, biological examinations, imaging and evaluation of daily impact. Basic treatments, including methotrexate and biotherapies in certain situations, are part of this personalized strategy. But the ARCTIC results do not provide individual instructions to intensify, stop or modify a medication.
The useful point, for the patient, is more concrete: if pain, swelling, fatigue or flare-ups remain present despite treatment, this merits a discussion with the rheumatologist on the objective set and the means to achieve it. Early remission appears here as a good signal for the future; above all, it must encourage regular, shared and adjusted monitoring before difficulties set in.